Oxiracetam
4-hydroxy-2-oxo-1-pyrrolidineacetamid · 2-(4-Hydroxy-2-oxopyrrolidin-1-yl)acetamide · ct-848 · isf2522 · Neurome · Olaxitam · Olacetam · Neuractiv
식별자 및 물리적 특성
| CAS No. | 62613-82-5 |
|---|---|
| 분자식 | C6H10N2O3 |
| 평균 분자량 | 158.16 g/mol |
| 단동위원소 질량 | 158.06914218 g/mol |
| SMILES | NC(=O)CN1CC(O)CC1=O |
| InChIKey | IHLAQQPQKRMGSS-UHFFFAOYSA-N |
| PubChem CID | 4626 |
| ChEMBL | CHEMBL36633 |
| ChEBI | CHEBI:134788 |
| EC No. | 636-370-0 |
| DTXSID | DTXSID9045180 |
화학 및 물리적 성질
| XLogP | -2.2 |
|---|---|
| 극성 표면적 | 83.6 |
| 수소 결합 공여자 수 | 2 |
| 수소 결합 수용자 수 | 3 |
| 회전 가능 결합 수 | 2 |
| 무거운 원자 수 | 11 |
| 형식 전하 | 0 |
| 복잡도 | 192 |
| 의약품 | DEA NFLIS-Drug Category -> Stimulants |
| 녹는점 | 165-168 °C |
| 끓는 점 | 494.6±40.0 °C(Predicted) |
| 밀도 | 1.416 |
| 저장 조건 | Sealed in dry,Room Temperature |
| 용해도 | DMSO (Slightly, Heated), Methanol (Slightly, Heated) |
| 물리적 상태 | 고체 |
| pKa(산도 계수) | 13.76±0.20(Predicted) |
| 색상 | 흰색에서 황백색까지 |
| Merck | 14,6942 |
| InChI | InChI=1S/C6H10N2O3/c7-5(10)3-8-2-4(9)1-6(8)11/h4,9H,1-3H2,(H2,7,10) |
| InChIKey | IHLAQQPQKRMGSS-UHFFFAOYSA-N |
| SMILES | N1(CC(N)=O)CC(O)CC1=O |
화학적 성질
Whie Solid
안전 및 규제
| GHS 분류 | WarningH315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]P264, P264+P265, P280, P302+P352, P305+P351+P338, P321, P332+P317, P337+P317, and P362+P364 (click each P-code to see the statement)Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Hazard Classes and Categories | Skin Irrit. 2 (100%) |
| 수질 위해 등급(WGK) | 3 |
| RTECS 번호 | UX9656638 |
| 관세 코드 | 2933.79.8500 |
| 위험 문구(R) | 36/38 |
| 위험 표시 | Xi |
| 안전 문구(S) | 26-36 |
| 저장 분류 | 11 - Combustible Solids |
용도
개요
Oxiracetam is a structural analogue of piracetam. This compound has enhancing effects on vigilance and memory. In comparison with piracetam, oxiracetam exhibits greater improvement in memory (Itil et al., 1986) and has been used extensively for the treatment of dementia, including AD, VaD, MID (Baumel et al., 1989; Dysken et al., 1989), and mixed forms. Green et al. (1992) failed to demonstrate a difference from placebo in AD patients. In contrast, Maina et al. (1989) studied 289 patients with MID in a double-blind placebo-controlled trial and after 12 weeks of treatment found that oxiracetam reduced behavioural symptoms.
용도
Oxiracetam is a 4-hydroxy analog of piracetam with psychostimulant activity, reportedly useful in relieving the symptoms of cerebral insufficiency in the elderly.